Navigation Links
Van Andel Research Institute findings provide more complete picture of kidney cancer
Date:12/29/2011

Grand Rapids, Mich. (December 29, 2011) Two recent studies by Van Andel Research Institute scientists are providing a foundation for a more complete understanding of distinct kidney cancer subtypes, which could pave the way for better treatments.

In a study published in Cancer Cell led by Kyle Furge, Ph.D. and Aikseng Ooi, Ph.D., researchers provide a more complete understanding of the biology of Type 2 papillary renal cell carcinoma (PRCC2), an aggressive type of kidney cancer with no effective treatment, which lays the foundation for the development of effective treatment strategies.

Despite obvious morphological, genetic, and clinical differences, hereditary PRCC2 is thought to share similar pathway deregulation due to genetic mutation with its counterpart, clear cell renal cell carcinoma (CCRCC), a subtype that accounts for 75% of all kidney cancers and that, unlike PRCC2, responds favorably to drugs targeting vascular endothelial growth factor (VEGF), a signal protein produced by cells that stimulate blood vessel formation.

The study, which included international collaboration with researchers from the National Cancer Centre Singapore, Gntique Oncologique EPFE-INSERM U753 and Facult de Mdecine Paris-Sud, Le Kremlin-Bictre and Institut de Cancrologie Gustave Roussy, Michigan State University, Northwestern Memorial Hospital, Cleveland Clinic, Singapore General Hospital, and The Wistar Institute, identified deregulation of the KEAP1-NRF2 signaling pathway as a factor that distinguishes PRCC2 from CCRCC, but links both hereditary and sporadic PRCC2.

In another study published in Cancer Research, led by Yan Ding, Ph.D., and Bin Tean Teh, Ph.D. and carried out in collaboration with the National Cancer Centre Singapore, researchers integrated gene expression profiling and RNAi screening data to identify genes involved in CCRCC development and progression.

In recent years, several molecularly targeted therapies such as sunitinib, sorafenib, and pazopanib, which target the receptor tyrosine kinases of VEGF have been approved for CCRCC. Although these therapies significantly extend overall survival, nearly all patients with advanced CCRCC eventually succumb to the disease.

Gene set enrichment analysis indicated that cell-cycle-related genes, in particular PLK1, were associated with disease aggressiveness. Further, the association of PLK1 in both disease aggression and in vitro growth prompted researchers to examine the effects of a small-molecule inhibitor in CCRCC cell lines. Their findings highlight PLK1 as a promising potential therapeutic target for CCRCC.


'/>"/>

Contact: Joe Gavan
joe.gavan@vai.org
616-234-5390
Van Andel Research Institute
Source:Eurekalert

Related medicine news :

1. Van Andel Institute study may lead to better, safer drug for diabetes
2. Van Andel Research Institute finding could lead to reduced side effects in anti-cancer antibiotics
3. Van Andel Research Institute finding is potential predictor of deadly cancer common in Asia
4. Chairman Al Brandel of Lions Clubs International Foundation to Appear in Washington DC's National Memorial Day Parade
5. AADR awards the 2010 Distinguished Mentoring Award to Irwin D. Mandel
6. Research!America Chair John Edward Porter says health research and prevention fared well in 2011
7. UT Southwestern research suggests new way to ensure effectiveness of TB treatment
8. President Obama and leading GOP presidential candidate support health research
9. Cleveland Clinic researchers honored for contributions to science
10. UK researchers present findings from Kentucky breast cancer patients with disease relapse
11. Pitt researchers propose new model to design better flu shots
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... 08, 2016 , ... Brenntag Specialties, Inc.(BSI) , is ... & Beverage and Dietary Supplement market segments across the western ... geographies east of the Rocky Mountains since 2012. Consistent performance in business ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Valentine’s Season is famous for gift giving with flowers, ... that they are loved. This year, for more than 5.6 million Americans suffering with ... won't be enough to remind them of the lives they’ve led and the people they’ve ...
(Date:2/8/2016)... ... , ... If you are feeling that your clothes are a tad snug, ... the Center for Disease Control and Prevention (CDC), 34.9% of U.S. adult women are ... cancer, some of the leading causes of preventable death. February is heart health ...
(Date:2/8/2016)... Indianapolis, IN (PRWEB) , ... February 08, 2016 ... ... serving the Indianapolis, IN metro area, has selected the latest beneficiary of their ... nonprofit organization dedicated to preventing bullying in area schools. Donations are now being ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... executive networking and relationship-marketing firm, announced today that nominations will be accepted ... Executive® (ISE®) West Awards. , Awards include the Information Security Executive® ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... 2016  Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) today ... ended December 31, 2015, the Company achieved revenue of $8,195,839, ... same quarter in fiscal 2015. --> ... fiscal year 2016 was $2,068,635, or $.03 per share, up ... share, in the Q2 of fiscal year 2015. Gross margin ...
(Date:2/8/2016)... http://www.researchandmarkets.com/research/bcrl3s/labelfree ) ... "Label-Free Detection Market by Technology, Products, Applications ... to their offering. --> http://www.researchandmarkets.com/research/bcrl3s/labelfree ... "Label-Free Detection Market by Technology, Products, ... report to their offering. --> ...
(Date:2/8/2016)... 2016  HemaFlo Therapeutics, Inc. announced today that the United ... Number 9,119,880 covering the use of NephroFlow to treat acute ... HemaFlo,s founder, said, "We are pleased to secure our rights ... Peterson , PhD, HemaFlo,s founder, said, "We are pleased to ... --> Dale Peterson , PhD, HemaFlo,s founder, said, ...
Breaking Medicine Technology: